Project

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Ongoing - recruitment active · 2023 until 2028

Hess Dagmar, Donno Monica, Quinter Janine